Welcome Guest
Home > Clinical Breast Cancer > Volume 7 |  Issue 6 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  TAXOL ® [package insert].Princeton, NJ: Bristol-Myers Squibb Company; 2003.
    2.  TAXOTERE ® [package insert].Bridgewater, NJ: Aventis Pharmaceuticals Inc.; 2003.
    3.  Loos WJ, ten Tije AJ, Verweij J, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42:665-685.
    4.  Desai N, Trieu V, Yao R, et al. Evidence of greater antitumor activity of Cremophorfree nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol: role of a novel albumin transporter mechanism. Presented at: the 26th Annual San Antonio Breast Cancer Symposium; December 36, 2003; San Antonio, TX.
    5.  Desai N, Ibrahim NK, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8:1038-1044.
    6.  Davidson N, Gradishar WJ, Tjulandin S, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803.
    7.  Cheporov S, Gradishar W, Krasnojon D, et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Presented at: the 29th Annual San Antonio Breast Cancer Symposium; December 1417, 2006; San Antonio, TX. Abstract #46.
    8.  Berry D, Cirrincione C, Seidman AD, et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastu-zumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Paper presented at: 40th Annual Meeting of the American Society of Clinical Oncology; June 58, 2004; New Orleans, LA. Abstract #512.
    9.  Berry DA, Winer EP, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 2004; 22:2061-2068.
    10.  Erban J, Jones SE, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-5551.
    11.  Dowsett M, Johnston SR, Martin LA, et al. Life following aromatase inhibitors--where now for endocrine sequencing?. Breast Cancer Res Treat 2005; 93(suppl 1):S19-S25.
    12.  Bajetta E, Lønning PE, Lønning PE, Lonning PE, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234-2244.
    13.  Ingle JN, Rowland KM, Suman VJ, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006; 24:1052-1056.
    14.  Hawle H, Paridaens R, Perey L, Thörlimann B, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-69.
    15.  Bartsch R, Steger GC, Steger GG, Wenzel C, et al. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:20 (Abstract #78)
    16.  Chia S, Gradishar W, Piccart M, et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Paper presented at: 29th Annual San Antonio Breast Cancer Symposium; December 1417, 2006; San Antonio, TX. Abstract #12..
    17.  Dang C, Hudis C. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg. Clin Breast Cancer 2006; 7:51-58.
    18.  Berry DA, Cirrincione C, Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431-1439.
    19.  Berry DA, Demetri GD, Henderson IC, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983.
    20.  Holmes FA, Jones SE, Savin MA, et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubi-cin/cyclophosphamide) in 1016 women with early stage breast cancer. Breast Cancer Res Treat 2005; 94(suppl 1):S20 (Abstract #40)
    21.  Bryant J, Lembersky B, Mamounas EP, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23:3686-3696.
    22.  Mackey J, Martin M, Pienkowski T, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-2313.
    23.  Mart¡n M, Rodr¡guez-Lescure A, Ruiz A, et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 trial. Breast Cancer Res Treat 2005; 94((suppl 1)):S20 (Abstract #39)
    24.  Fumoleau P, Roché H, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004; 88(suppl 1):S16 (Abstract #27)
    25.  Mauriac L, Therasse P, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21:843-850.
    26.  Burnell M, Chapman JA, Levine M, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA. 21: results of an interim analysis. Paper presented at: 29th Annual San Antonio Breast Cancer Symposium; December 1417, 2006; San Antonio, TX. Abstract #53.
    27.  Clark GM, Slamon DJ, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
    28.  Leyland-Jones B, . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
    29.  Bryant J, Perez EA, Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
    30.  Leyland- Jones B, Leyland-Jones B, Piccart-Gebhart MJ, Procter M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
    31.  Eiermann W, Robert N, Slamon D, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006; 100
    32.  Godolphin W, Jones L, Jones LA, Slamon D, Slamon DJ, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
    33.  Ariazi E, O’ Regan RM, Osipo C, et al. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 2006; 12:2255-2263.
    34.  Arpino G, Wakeling AE, Weiss H, et al. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab and pertuzumab to block HER2 crosstalk with ER and restore tamoxifen inhibition. Breast Cancer Res Treat 2004; 88:S15 (Abstract #23)
    35.  Detre S, Gutierrez MC, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23:2469-2476.
    36.  Harris L, Isaacs C, Marcom PK, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2006
    37.  Clemens M, Kaufman B, Mackey J, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2positive metastatic breast cancer. Breast Cancer Res Treat 2006; 95:(Abstract #3)
    38.  Cuzick J, Dowsett M, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005; 23:7512-7517.
    39.  Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007
    40.  Coombes RC, Gibson LJ, Hall E, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
    41.  Coop A, Ellis MJ, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-3816.
    42.  Dowsett M, Ebbs SR, Smith IE, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23:5108-5116.
    43.  Allred DC, Dowsett M, on behalf of the TransATAC investigators, et al. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 1417, 2006; San Antonio, TX. Abstract #48.
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume 7
  •  Issue 6
    • Publication Date: February 2007


Highlights from: The 29th Annual San Antonio, Breast Cancer Symposium; San Antonio, TX; December 2006


Aarati Ranganathan, Zachary Moore, Joyce A. O’ Shaughnessy


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. Pengeluaran SDY